ec054d40-e5b8-496a-8c99-5e7f88f2cf37
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.550
- HEDGEHOG_SIGNALING+0.490
- UV_RESPONSE_DN+0.450
- ALLOGRAFT_REJECTION+0.430
- IL6_JAK_STAT3_SIGNALING+0.420
- INTERFERON_GAMMA_RESPONSE+0.420
- INTERFERON_ALPHA_RESPONSE+0.410
- KRAS_SIGNALING_UP+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.490
- MYC_TARGETS_V1-0.460
- DNA_REPAIR-0.440
- MYC_TARGETS_V2-0.410
- E2F_TARGETS-0.390
- FATTY_ACID_METABOLISM-0.360
- MTORC1_SIGNALING-0.330
- GLYCOLYSIS-0.320
- PEROXISOME-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.950 |
| 2 | 80cb0e05-387d-4bd8-b49c-ff2aae043982 | — | — | 0.949 |
| 3 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.945 |
| 4 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.942 |
| 5 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.939 |
| 6 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.934 |
| 7 | 67ed15bc-bbe5-4da7-81f9-002c54483f67 | — | — | 0.932 |
| 8 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.930 |
| 9 | SRR12202441 | — | — | 0.926 |
| 10 | 59f108c6-677f-4cf2-89fd-6bd15133dd6f | — | — | 0.922 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.490 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.450 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |